Indivior (OTCMKTS:INVVY) vs. Reliv’ International (OTCMKTS:RELV) Critical Comparison

Indivior (OTCMKTS:INVVY) and Reliv’ International (OTCMKTS:RELV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Indivior and Reliv’ International”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81
Reliv’ International	$35.06 million	0.11	-$440,000.00	($0.09)	-25.00

Indivior has higher revenue and earnings than Reliv’ International. Reliv’ International is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.1% of Indivior shares are owned by institutional investors. Comparatively, 7.8% of Reliv’ International shares are owned by institutional investors. 30.0% of Reliv’ International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Indivior has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Reliv’ International has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Profitability

This table compares Indivior and Reliv’ International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	N/A	N/A	N/A
Reliv’ International	-0.61%	-1.89%	-1.31%

Analyst Ratings

This is a breakdown of recent ratings for Indivior and Reliv’ International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	0	1	0	3.00
Reliv’ International	0	0	0	0	0.00

Indivior currently has a consensus price target of $50.00, suggesting a potential upside of 128.88%. Given Indivior’s stronger consensus rating and higher possible upside, research analysts plainly believe Indivior is more favorable than Reliv’ International.

Summary

Indivior beats Reliv’ International on 12 of the 14 factors compared between the two stocks.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.